Brokers Set Expectations for Elevance Health Q3 Earnings

2025-04-26T07:11:02Z

Elevance Health, Inc. (NYSE:ELV – Free Report) – Analysts at Leerink Partnrs lowered their Q3 2025 EPS estimates for shares of Elevance Health in a research note issued on Tuesday, April 22nd. Leerink Partnrs analyst W. Mayo now expects that the company will earn $8.39 per share for the quarter, down from their prior estimate of $8.56. The consensus estimate for Elevance Health’s current full-year earnings is $33.96 per share. Leerink Partnrs also issued estimates for Elevance Health’s Q4 2025 earnings at $4.03 EPS, FY2025 earnings at $34.37 EPS, Q3 2026 earnings at $9.87 EPS, Q4 2026 earnings at $5.03 EPS, FY2026 earnings at $39.20 EPS, FY2027 earnings at $45.47 EPS, FY2028 earnings at $52.24 EPS and FY2029 earnings at $60.19 EPS.

Get Elevance Health alerts:

Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The company reported $11.97 earnings per share for the quarter, beating the consensus estimate of $10.60 by $1.37. The company had revenue of $48.77 billion for the quarter, compared to analyst estimates of $46.26 billion. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%.

ELV has been the topic of several other research reports. Argus raised shares of Elevance Health from a “hold” rating to a “buy” rating and set a $450.00 target price on the stock in a report on Monday, March 17th. Barclays increased their price target on Elevance Health from $512.00 to $522.00 and gave the stock an “overweight” rating in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $478.00 price objective on shares of Elevance Health in a research report on Wednesday. StockNews.com upgraded Elevance Health from a “hold” rating to a “buy” rating in a report on Thursday, March 20th. Finally, Robert W. Baird reiterated a “neutral” rating and set a $529.00 price target (down previously from $625.00) on shares of Elevance Health in a research report on Tuesday, April 15th. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $509.44.

Check Out Our Latest Research Report on Elevance Health

Elevance Health Stock Performance

Shares of NYSE:ELV opened at $421.55 on Thursday. The stock has a market capitalization of $95.43 billion, a price-to-earnings ratio of 16.46, a price-to-earnings-growth ratio of 1.18 and a beta of 0.77. The business’s fifty day moving average price is $420.00 and its two-hundred day moving average price is $408.48. Elevance Health has a fifty-two week low of $362.21 and a fifty-two week high of $567.26. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th will be paid a $1.71 dividend. The ex-dividend date is Tuesday, June 10th. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.62%. Elevance Health’s dividend payout ratio (DPR) is presently 26.71%.

Insider Activity at Elevance Health

In other Elevance Health news, CFO Mark Kaye sold 4,588 shares of the stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $424.82, for a total value of $1,949,074.16. Following the completion of the sale, the chief financial officer now owns 18,977 shares in the company, valued at $8,061,809.14. This trade represents a 19.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total value of $1,388,635.20. Following the transaction, the executive vice president now directly owns 10,116 shares in the company, valued at approximately $4,008,970.80. This trade represents a 25.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,535 shares of company stock worth $3,521,612 in the last ninety days. Company insiders own 0.29% of the company’s stock.

Hedge Funds Weigh In On Elevance Health

Several large investors have recently modified their holdings of ELV. Mutual Advisors LLC raised its holdings in Elevance Health by 2.5% in the 4th quarter. Mutual Advisors LLC now owns 2,163 shares of the company’s stock valued at $833,000 after acquiring an additional 52 shares during the period. Czech National Bank boosted its stake in Elevance Health by 6.5% in the 4th quarter. Czech National Bank now owns 50,286 shares of the company’s stock valued at $18,551,000 after purchasing an additional 3,049 shares during the period. Diversified Trust Co grew its holdings in Elevance Health by 13.7% in the 4th quarter. Diversified Trust Co now owns 22,576 shares of the company’s stock valued at $8,328,000 after buying an additional 2,725 shares in the last quarter. JB Capital LLC increased its position in Elevance Health by 597.2% during the 4th quarter. JB Capital LLC now owns 9,384 shares of the company’s stock worth $3,462,000 after buying an additional 8,038 shares during the period. Finally, Tidal Investments LLC lifted its holdings in shares of Elevance Health by 60.6% during the third quarter. Tidal Investments LLC now owns 10,485 shares of the company’s stock worth $5,452,000 after buying an additional 3,956 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Company Profile

(Get Free Report)

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.